ERBB2 and gastric cancer: Since there are presently no clinical trials for the use of drug conjugates for OCCC, it might be desirable to experiment new therapeutical strategies for HER2-low phenotype in order to obtain a considerable improvement in the overall survival of such patients, similarly to breast and gastric cancers, for which the recent evolving issue of HER2 landscape is of increasing clinical impact.